RS50053B - OXYCODONOUS CONTROLLED DISPOSALS - Google Patents

OXYCODONOUS CONTROLLED DISPOSALS

Info

Publication number
RS50053B
RS50053B YUP-708/04A YU70804A RS50053B RS 50053 B RS50053 B RS 50053B YU 70804 A YU70804 A YU 70804A RS 50053 B RS50053 B RS 50053B
Authority
RS
Serbia
Prior art keywords
oxycodone
formulation
administration
controlled
hours
Prior art date
Application number
YUP-708/04A
Other languages
Serbian (sr)
Inventor
Benjamin OSHLACK
John Joseph Minogue
Robert Francis Kaiko
Mark Chasin
Original Assignee
Euro-Celtique S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A., filed Critical Euro-Celtique S.A.,
Publication of YU70804A publication Critical patent/YU70804A/en
Publication of RS50053B publication Critical patent/RS50053B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oralna formulacija oksikodona sa kontrolisanim otpuštanjem za humane pacijente, naznačena time, što se sastoji od: (a) soli oksikodona u količini koj a je ekvivalentna 10 mg do 160 mg oksikodon hidrohloridne soli i (b) matrice sa kontrolisanim doznim otpuštanjem, koja je drugačija od matrice akrilne smole, izabrane tako da formulacij a obezbeđuje pH nezavisne karakteristike rastvaranja, (c) gde pomenuta formulacija obezbeđuje, pri ravnotežnom stanju posle ponovljenog davanja u intervalima od 12 sati, srednju maksimalnu koncentraciju oksikodona u plazmi od 6 do 240 ng/ml u toku 2 do 4.5 sati posle davanja i srednj u minimalnu koncentracij u oksi kodona u plazmi od 3 do 120 ng/ml u toku 10 do 14 sati posle davanja.Prijava sadrži još 6 zahteva.Oral controlled release oxycodone formulation for human patients comprising: (a) an oxycodone salt in an amount a equivalent to 10 mg to 160 mg oxycodone hydrochloride salt and (b) a controlled dose release matrix, which is different from an acrylic resin matrix selected so that formulation a provides pH independent dissolution characteristics, (c) wherein said formulation provides, at steady state after repeated administration at 12 hour intervals, a mean maximum plasma oxycodone concentration of 6 to 240 ng / ml in during 2 to 4.5 hours after administration and medium to minimum concentrations in the plasma oxy codon from 3 to 120 ng / ml for 10 to 14 hours after administration. The application contains 6 more requirements.

YUP-708/04A 1992-11-25 1993-05-21 OXYCODONOUS CONTROLLED DISPOSALS RS50053B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21014692A 1992-11-25 1992-11-25

Publications (2)

Publication Number Publication Date
YU70804A YU70804A (en) 2005-11-28
RS50053B true RS50053B (en) 2008-11-28

Family

ID=47559778

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-708/04A RS50053B (en) 1992-11-25 1993-05-21 OXYCODONOUS CONTROLLED DISPOSALS

Country Status (2)

Country Link
RS (1) RS50053B (en)
YU (3) YU20050408A (en)

Also Published As

Publication number Publication date
YU20050408A (en) 2006-05-25
YU20050409A (en) 2006-05-25
YU20050410A (en) 2006-05-25
YU70804A (en) 2005-11-28

Similar Documents

Publication Publication Date Title
YU49495B (en) Controlled release oxycodone formulation and their use
Richter-Levin et al. Activation of metabotropic glutamate receptors is necessary for long-term potentiation in the dentate gyrus and for spatial learning
Borison et al. Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?
LV10684A (en) Regular release of morphine islet containing content
DE122011100032I1 (en) Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors.
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
SE8901593L (en) LONG-TERM DICLOFENAK SODIUM PREPARATION
ATE202926T1 (en) PHARMACEUTICAL EFFECTIVE PREPARATIONS CONTAINING BIODEGRADABLE MICROCAPSULES FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS
DK0904067T3 (en) Transdermally administered dextromethorpane as a cough suppressant
ATE135909T1 (en) METHOD FOR TREATING ACNE
DE69726255D1 (en) USE OF VALACICLOVIR FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GENITALHERPES BY ONE-TIME ADMINISTRATION
BR9607541A (en) Treatment of diseases caused by the cytokine growth factor
Theobald Jr The effect of arylazido aminopropionyl ATP on atropine resistant contractions of the cat urinary bladder
RS50053B (en) OXYCODONOUS CONTROLLED DISPOSALS
Wurtman et al. Dietary enhancement of CNS neurotransmitters
Russell et al. Central cholinergic involvement in behavioral hyper-reactivity
KR20040020054A (en) Prevention of addiction in pain management
Hiramoto et al. Effect of reserpine on retention of the conditioned NK cell response
Needham et al. Effects of octopamine, chlordimeform, and demethylchlordimeform on amine-controlled tick salivary glands isolated from feeding Amblyomma americanum (L.)
KR20050032590A (en) Medicament and method for reducing alcohol and/or tobacco consumption
RS50058B (en) OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
MY110769A (en) Controlled release oxycodone compositions.
Diamond et al. Differentiation of Phenylethylamine (PE)-and Amphetamine (AMPH)-Induced Behaviors
IT1317079B1 (en) USE OF ISOVALERIL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.